Non-invasive energy upconversion methods and systems

Patent metadata

Field	Value
Publication number	US-9526913-B2
Application number	US-201414168795-A
Country	US
Kind code	B2
Filing date	Jan 30, 2014
Priority date	Nov 6, 2007
Publication date	Dec 27, 2016
Grant date	Dec 27, 2016

Abstract

A nanoparticle-based system for enhancement of emitted light inside a medium. The nanoparticle-based system includes a phosphorescent material which, upon activation, produces the emitted light, and a metallic structure attached to the phosphorescent material. The metallic structure has a surface plasmon resonance which resonates at a frequency which spectrally overlaps with one or more frequencies of the emitted light.

First claim

The invention claimed is:

1. A system for production of emitted light inside a medium to be treated for a disease or disorder, comprising:
a sterile medium comprising a pharmaceutical carrier;
a first phosphorescent material which, upon activation, produces said emitted light, wherein said phosphorescent material has an upconversion capability to produce, from a first wavelength λ 1 of radiation, an up-converted light of a second wavelength λ 2 in a visible or near-infrared or infrared frequency band; and
a second phosphorescent material having a down conversion capability to produce, upon x-ray exposure, down converted light in an ultraviolet frequency band for treatment of the disease or disorder.

2. The system of claim 1 , wherein said first phosphorescent material comprises an upconverting phosphor.

3. The system of claim 1 , wherein said first phosphorescent material comprises a trivalent rare earth ion.

4. The system of claim 3 , wherein said first phosphorescent material further comprises a monovalent alkali metal.

5. The system of claim 3 , wherein said first phosphorescent material further comprises a second trivalent rare earth element.

6. The system of claim 3 , wherein said first phosphorescent material further comprises a third trivalent rare earth element.

7. The system of claim 6 , wherein said first phosphorescent material comprises Tm 3+ .

8. The system of claim 6 , wherein said first phosphorescent material comprises Er 3+ .

9. The system of claim 6 , wherein said first phosphorescent material comprises Y 3+ .

10. The system of claim 6 , wherein said first phosphorescent material comprises Yb 3+ .

11. The system of claim 1 , wherein said first phosphorescent material comprises a material selected from the group consisting of a Group 15, 16 and 17 element.

12. The system of claim 11 , wherein said first phosphorescent material comprises a material selected from the group consisting of a Group 17 element.

13. The system of claim 12 , wherein said Group 17 element comprises F − .

14. The system of claim 4 , wherein said monovalent alkali metal comprises Na+.

15. The system of claim 1 , further comprising a fluorescent tag.

16. The system of claim 1 , further comprising a magnetic material.

17. The system of claim 1 , wherein the first phosphorescent material comprises at least one of Y 2 O 3 , Y 2 O 2 S, NaYF 4 , NaYbF 4 , YAG, YAP, Nd 2 O 3 , LaF 3 , LaCl 3 , La 2 O 3 , TiO 2 , LuPO 4 , YVO 4 , YbF 3 , YF 3 , Na-doped YbF 3 , or SiO 2 or alloys or layers thereof.

18. The system of claim 1 , wherein the first phosphorescent material is configured to exhibit ultraviolet emission upon interaction with a first wavelength λ 1 .

19. The system of claim 1 , wherein the first phosphorescent material is configured to exhibit at least one of infrared, visible, and ultraviolet emission upon interaction with a first wavelength λ 1 .

20. The system of claim 19 , wherein the first phosphorescent material and the second phosphorescent material comprises a plurality of nanoparticles including respectively at least one of a first group which exhibits a visible emission upon interaction with a first wavelength λ 1 and a second group which exhibits ultraviolet emission upon interaction with the first wavelength λ 1 .

21. The system of claim 20 , where the first group comprises a diagnostic group for producing imaging light showing a position of the first group in said medium, and the second group comprises a reaction-stimulating group producing a photostimulated reaction.

22. The system of claim 1 , further comprising a recipient linked to either said first or second phosphorescent material by a chemical moiety.

23. The system of claim 22 , wherein a length of the chemical moiety increases a reactivity of the recipient.

24. The system of claim 22 , wherein the recipient comprises a photoactivatable drug.

25. The system of claim 24 , wherein the photoactivatable drug comprises at least one of a psoralen, pyrene cholesteryloleate, acridine, porphyrin, fluorescein, rhodamine, 16-diazorcortisone, ethidium, transition metal complexes of bleomycin, transition metal complexes of deglycobleomycin organoplatinum complexes, alloxazines, vitamin Ks, vitamin L, vitamin metabolites, vitamin precursors, naphthoquinones, naphthalenes, naphthols and derivatives thereof having planar molecular conformations, porphorinporphyrins, dyes and phenothiazine derivatives, coumarins, quinolones, quinones, and anthroquinones, and porphycene, rubyrin, rosarin, hexaphyrin, sapphyrin, chlorophyl, chlorin, phthalocynine, porphyrazine, bacteriochlorophyl, pheophytin, texaphyrin macrocyclic-based component, or a metalated derivative thereof.

26. The system of claim 22 , wherein the recipient comprises at least one of a laser dye, a fluorophore, a lumophore, or a phosphor.

27. The system of claim 26 , wherein the laser dye comprises at least one of p-terphenyl, sulforhodamine B, p-quaterphenyl, Rhodamine 101, curbostyryl 124, cresyl violet perchlorate, popop, DODC iodide, coumarin 120, sulforhodamine 101, coumarin 2, oxozine 4 perchlorate, coumarin 339, PCM, coumarin 1, oxazine 170 perchlorate, coumarin 138, nile blue A perchlorate, coumarin 106, oxatine 1 perchlorate, coumarin 102, pyridine 1, coumarin 314T, styryl 7, coumarin 338, HIDC iodide, coumarin 151, PTPC iodide, coumarin 4, cryptocyanine, coumarin 314, DOTC iodide, coumarin 30, HITC iodide, coumarin 500, HITC perchlorate, coumarin 307, PTTC iodide, coumarin 334, DTTC perchlorate, coumarin 7, IR-144, coumarin 343, HDITC perchlorate, coumarin 337, IR-NO, coumarin 6, IR-132, coumarin 152, IR-125, coumarin 153, boron-dipyrromethere, HPTS, flourescein, rhodamine 110,2,7-dichlorofluorescein, rhodamine 65, and rhodamin 19 perchlorate, rhodamine b, and derivatives thereof.

28. The system of claim 1 , wherein a metallic structure is attached to either said first or second phosphorescent material; and said metallic structure having a surface plasmon resonance which resonates at a frequency which spectrally overlaps with one or more frequencies of said emitted light.

29. The system of claim 28 , wherein said metallic structure comprises at least one of a first metal and a second metal.

30. The system of claim 29 , wherein the first and second metals comprise at least one or more transition metals.

31. The system of claim 29 , wherein said first metal is selected from the group consisting of Au, Ag, and Pt.

32. The system of claim 31 , wherein said second metal is selected from the group consisting of Au, Ag, and Pt.

33. The system of claim 28 , wherein the metallic structure comprises at least one of a spherical shell, an oblate shell, a crescent shell, or a multilayer shell.

34. A materials system for production of emitted light inside a medium to be treated for a disease or disorder, comprising:
a sterile medium comprising a pharmaceutical carrier including a photoactivatable drug;
a first group of phosphors which, upon activation, produces said emitted light visible light; and
a second group of phosphors having a down conversion capability which, upon x-ray exposure, produces down converted light for treatment of the disease or disorder.

35. A system for production of emitted light inside a medium to be

Assignees

• Immunolight Llc
• Univ Duke

Inventors

• Vo-Dinh Tuan
• Scaffidi Jonathan P
• Chada Venkata Gopal Reddy
• Lauly Benoit
• Zhang Yan
• Gregas Molly K
• Stanton Ian Nicholas
• Stecher Joshua T
• Therien Michael J
• Bourke Jr Frederic A
• Walder Harold
• Fathi Zak
• Ayres Jennifer A
• Zhang Zhenyuan
• Simmons Joseph H
• Norton Stephen John

Classifications

• A61P9/08

  Vasodilators for multiple indications · CPC title

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P9/06

  Antiarrhythmics · CPC title

• A61P9/14

  Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers · CPC title